Molecular Medicine最新文献

筛选
英文 中文
Purine-rich element binding protein alpha: a DNA/RNA binding protein with multiple roles in cancers.
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-22 DOI: 10.1186/s10020-025-01087-8
Shiyi Yu, Chengyang Jiang, Yawen Yang, Fei Cheng, Fangchen Liu, Chang Liu, Xue Gong
{"title":"Purine-rich element binding protein alpha: a DNA/RNA binding protein with multiple roles in cancers.","authors":"Shiyi Yu, Chengyang Jiang, Yawen Yang, Fei Cheng, Fangchen Liu, Chang Liu, Xue Gong","doi":"10.1186/s10020-025-01087-8","DOIUrl":"https://doi.org/10.1186/s10020-025-01087-8","url":null,"abstract":"<p><p>Proteins that bind to DNA/RNA are typically evolutionarily conserved with multiple regulatory functions in transcription initiation, mRNA translation, stability of RNAs, and RNA splicing. Therefore, dysregulation of DNA/RNA binding proteins such as purine-rich element binding protein alpha (PURα) disrupts signaling transduction and often leads to human diseases including cancer. PURα was initially recognized as a tumor suppressor in acute myeloid leukemia (AML) and prostate cancer (PC). Most recently, several studies have revealed that PURα is dysregulated in multiple cancers, such as breast cancer (BC) and esophageal squamous cell carcinoma (ESCC). The oncogenic or tumor-suppressive functions of PURα are realized via regulating RNA/protein interaction, mRNA translation, formation of stress granules (SGs), and transcriptional regulation of several oncogenes and tumor suppressors. Although DNA/RNA binding proteins are hardly targeted, novel strategies have been applied to identify compounds targeting PURα and have demonstrated promising anti-tumor efficacy in the preclinical study. The present review summarizes the most recently discovered critical roles of PURα in various cancer types, providing an overview of the biomarker and therapeutic target potential of PURα for patients with cancer.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"20"},"PeriodicalIF":6.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergistic attenuation of complete freund's adjuvant-induced inflammation in mice using shinbaro-pelubiprofen: a novel therapeutic complex. 使用shinbaro-pelubiprofen在小鼠中协同衰减完全freund佐剂诱导的炎症:一种新的治疗复合物。
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-21 DOI: 10.1186/s10020-025-01083-y
Hyunseong Kim, Jin Young Hong, Wan-Jin Jeon, Hyun Kim, Changhwan Yeo, Junseon Lee, Yoon Jae Lee, In-Hyuk Ha
{"title":"Synergistic attenuation of complete freund's adjuvant-induced inflammation in mice using shinbaro-pelubiprofen: a novel therapeutic complex.","authors":"Hyunseong Kim, Jin Young Hong, Wan-Jin Jeon, Hyun Kim, Changhwan Yeo, Junseon Lee, Yoon Jae Lee, In-Hyuk Ha","doi":"10.1186/s10020-025-01083-y","DOIUrl":"10.1186/s10020-025-01083-y","url":null,"abstract":"<p><strong>Background: </strong>Inflammation is a critical protective response in the body, essential for combating infections and healing injuries. However, chronic inflammation can be harmful and significantly contribute to the development and progression of chronic diseases, with macrophage-mediated responses being central to these processes. This study presents \"SBR-Pel,\" a new therapeutic blend of Shinbaro tab (SBR), a traditional herbal formula, and pelubiprofen (Pel), a non-steroidal anti-inflammatory drug, and investigated their combined anti-inflammatory effects to create a treatment that both improves efficacy and reduces side effects.</p><p><strong>Methods: </strong>To this end, we performed both in vitro and in vivo analyses, utilizing a mouse model of inflammation. Viability and cytotoxicity assays, immunohistochemistry, enzyme-linked immunosorbent assays, real-time polymerase chain reaction assays, nociception assays, writhing tests, and blood biochemical analyses were performed.</p><p><strong>Results: </strong>In vitro, SBR-Pel synergistically reduced the production of nitric oxide and reactive oxygen species and the expression of pro-inflammatory cytokines. SBR-Pel also significantly attenuated paw edema in vivo in a Complete Freund's adjuvant-induced inflammation model in adult mice. Furthermore, immunohistochemical analyses showed that treatment with SBR-Pel reduced both the infiltration of CD68<sup>+</sup> macrophages and the expression of pro-inflammatory cytokines in inflamed tissues. Additionally, compared with individual treatment alone, SBR-Pel enhanced the expression of anti-inflammatory cytokines CD206, TGF-β, and IL-10, indicating a synergistic effect. Our research demonstrates that SBR-Pel effectively diminishes inflammatory pain by reducing macrophage infiltration and pro-inflammatory cytokine secretion. Additionally, while 1.5 mg/kg of Pel alone increases levels of liver and kidney toxicity markers, such as aspartate aminotransferase, alanine aminotransferase, and creatinine, combining it with SBR at a reduced dosage of 0.5 mg/kg maintains these markers at normal levels.</p><p><strong>Conclusions: </strong>This combined effect highlights SBR-Pel's potential as an effective treatment for inflammatory diseases driven by heightened macrophage activity, while also minimizing side effects by reducing the Pel dosage.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"17"},"PeriodicalIF":6.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article. 内分泌和代谢改变对全身性炎症和败血症的反应:综述文章。
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-21 DOI: 10.1186/s10020-025-01074-z
Syed Faizan Mehdi, Muhammad Hamza Qureshi, Salman Pervaiz, Karishma Kumari, Edwin Saji, Mahnoor Shah, Ahmad Abdullah, Kamran Zahoor, Hafiza Amna Qadeer, Disha Kumari Katari, Christine Metz, Lopa Mishra, Derek LeRoith, Kevin Tracey, Michael J Brownstein, Jesse Roth
{"title":"Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article.","authors":"Syed Faizan Mehdi, Muhammad Hamza Qureshi, Salman Pervaiz, Karishma Kumari, Edwin Saji, Mahnoor Shah, Ahmad Abdullah, Kamran Zahoor, Hafiza Amna Qadeer, Disha Kumari Katari, Christine Metz, Lopa Mishra, Derek LeRoith, Kevin Tracey, Michael J Brownstein, Jesse Roth","doi":"10.1186/s10020-025-01074-z","DOIUrl":"10.1186/s10020-025-01074-z","url":null,"abstract":"<p><p>Severe sepsis is cognate with life threatening multi-organ dysfunction. There is a disturbance in endocrine functions with alterations in several hormonal pathways. It has frequently been linked with dysfunction in the hypothalamic pituitary-adrenal axis (HPA). Increased cortisol or cortisolemia is evident throughout the acute phase, along with changes in the hypothalamic pituitary thyroid (HPT) axis, growth hormone-IGF-1 axis, insulin-glucose axis, leptin, catecholamines, renin angiotensin aldosterone axis, ghrelin, glucagon, hypothalamic pituitary gonadal (HGA) axis, and fibroblast growth factor-21. These changes and metabolic alterations constitute the overall response to infection in sepsis. Further research is essential to look into the hormonal changes that occur during sepsis, not only to understand their potential relevance in therapy but also because they may serve as prognostic indicators.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"16"},"PeriodicalIF":6.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11752782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
D-mannose promotes diabetic wound healing through inhibiting advanced glycation end products formation in keratinocytes. d -甘露糖通过抑制角化细胞中晚期糖基化终产物的形成来促进糖尿病伤口愈合。
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-18 DOI: 10.1186/s10020-025-01070-3
Jialiang Luo, Tianxing Wu, Jing Zhang, Zhicheng Liang, Weijie Shao, Di Wang, Lei Li, Daming Zuo, Jia Zhou
{"title":"D-mannose promotes diabetic wound healing through inhibiting advanced glycation end products formation in keratinocytes.","authors":"Jialiang Luo, Tianxing Wu, Jing Zhang, Zhicheng Liang, Weijie Shao, Di Wang, Lei Li, Daming Zuo, Jia Zhou","doi":"10.1186/s10020-025-01070-3","DOIUrl":"10.1186/s10020-025-01070-3","url":null,"abstract":"<p><strong>Background: </strong>Diabetic chronic foot ulcers pose a significant therapeutic challenge around the world, resulting in adverse effects and complications in patients. D-mannose is enriched in cirtus peel and exerts beneficial effects among various diseases, especially against inflammation-related disorders.</p><p><strong>Methods: </strong>Here, we examined the potential effect of D-mannose during wound healing process in streptozotocin (STZ)-induced diabetes mice in vivo and by culturing keratinocytes under high glucose condition in vitro. The skin lesion healing was recorded in photos and evaluated by histochemical staining. What's more, the advanced glycation end products (AGEs) concentration in blood and mice skin was quantified. Apoptotic cells were assessed by flow cytometry and Western blotting. Inflammatory cytokines and cellular differential gene expression levels were measured by real-time PCR. The expression of the AMPK/Nrf2/HO-1 signaling-related molecules was determined by Western blotting.</p><p><strong>Results: </strong>We first found that topical supplementation of D-mannose remarkably improved skin wound healing in diabetes mice. Furthermore, both in vivo and in vitro experiments demonstrated that D-mannose reduced the AGEs generation. Mechanistically, D-mannose inhibited AGEs, then upregulated AMPK/Nrf2/HO-1 signaling in the context of high glucose to maintain keratinocyte normal functions, which positively influenced macrophage and fibroblast to accelerate diabetic wound healing. Noteworthily, these protective effects of D-mannose were abolished by the pretreatment with inhibitors of AGEs or AMPK.</p><p><strong>Conclusion: </strong>As far as we know, this is the first study exploring the protective role of D-mannose on diabetic wound healing via topical supplementation. We find that D-mannose protects keratinocytes from high glucose stimulation via inhibition of AGEs formation as well as orchestrates inflammatory microenvironment in diabetic wounded skin, suggesting its supplementation as a potential therapy to promote refractory wound healing in diabetic patients.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"15"},"PeriodicalIF":6.0,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microbially produced imidazole propionate impairs prostate cancer progression through PDZK1. 微生物产生的咪唑丙酸通过PDZK1损害前列腺癌的进展。
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-16 DOI: 10.1186/s10020-025-01073-0
Shengkai Jin, Yuhua Zhou, Jing Lv, Yichen Lu, Yuwei Zhang, Menglu Li, Ninghan Feng
{"title":"Microbially produced imidazole propionate impairs prostate cancer progression through PDZK1.","authors":"Shengkai Jin, Yuhua Zhou, Jing Lv, Yichen Lu, Yuwei Zhang, Menglu Li, Ninghan Feng","doi":"10.1186/s10020-025-01073-0","DOIUrl":"10.1186/s10020-025-01073-0","url":null,"abstract":"<p><strong>Background: </strong>A close relationship exists between castration-resistant prostate cancer (CRPC) and histidine metabolism by gut microbes. However, the effects of the histidine metabolite imidazole propionate (IMP) on prostate cancer (PCa) and its underlying mechanisms are not well understood.</p><p><strong>Methods: </strong>We first assessed the effects of IMP on cell proliferation and migration at the cellular level. Subsequently, we investigated the mechanism of action of IMP using transcriptome sequencing, qPCR, and Western blot analysis. Finally, we validated our findings in vivo using a mouse model.</p><p><strong>Results: </strong>Histidine had no effect on PCa cell proliferation; however, IMP significantly inhibited the proliferation and migration of PC3 and DU145 cells. Mechanistic studies indicate that IMP exerts its effects by upregulating PDZK1 expression, which subsequently inhibits the phosphorylation of the PI3K-AKT pathway.</p><p><strong>Conclusions: </strong>In conclusion, IMP significantly inhibits the progression of PCa, offering new insights into potential treatments for CRPC.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"14"},"PeriodicalIF":6.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nootkatone inhibits the progression of glioblastoma by activating the ATF4-CHOP-CHAC1 pathway. 诺卡酮通过激活ATF4-CHOP-CHAC1通路抑制胶质母细胞瘤的进展。
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-16 DOI: 10.1186/s10020-025-01064-1
Qian Wang, Xiumin Xue, Zhichao Chen, Wei Zhang, Yiming Qian, Danni Chen, Lin Lin, Yinfeng Yuan, Weiqiao Zhao, Zhihui Huang, Yongjie Wang
{"title":"Nootkatone inhibits the progression of glioblastoma by activating the ATF4-CHOP-CHAC1 pathway.","authors":"Qian Wang, Xiumin Xue, Zhichao Chen, Wei Zhang, Yiming Qian, Danni Chen, Lin Lin, Yinfeng Yuan, Weiqiao Zhao, Zhihui Huang, Yongjie Wang","doi":"10.1186/s10020-025-01064-1","DOIUrl":"10.1186/s10020-025-01064-1","url":null,"abstract":"<p><p>Glioblastoma multiforme (GBM) represents a primary brain tumor that is widely prevalent, and clinical drugs available for its treatment exhibit varying degrees of resistance. Nootkatone (NKT) is a functional sesquiterpene sourced from traditional Chinese medicine --Alpinia Oxyphylla Miq and has been reported to have a diverse range of pharmacological properties. However, it remains unknown whether there are effects of NKT on GBM. In this study, we found that NKT inhibited the growth of GBM cells in a dose-dependent manner in vitro. Subsequently, we observed that NKT suppressed the migration and arrested cell cycle at G2/M phase of GBM cells. Furthermore, NKT induced the death of GBM cells accompanied by an increase in reactive oxygen species (ROS) production. Mechanistically, we found that NKT inhibited the progression of GBM cells through activating the ATF4-CHOP-CHAC1 pathway in GBM cells. Furthermore, NKT-induced inhibition of migration and proliferation in GBM cells was partially restored by ATF4 or CHAC1 knockdown. Finally, we found that NKT inhibited the growth of tumor in GBM orthotopic mice model through activation of ATF4-CHOP-CHAC1 axis. Taken together, our findings show that NKT suppresses the growth and migration of GBM cells by activating the ATF4-CHOP-CHAC1 pathway, which in turn prevents the tumorigenesis of GBMs and provides a novel perspective for the development of drugs against GBM.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"13"},"PeriodicalIF":6.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11737244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The systemic evolutionary theory of the origin of cancer (SETOC): an update. 癌症起源的系统进化理论(SETOC):更新。
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-14 DOI: 10.1186/s10020-025-01069-w
Antonio Mazzocca, Giovanni Ferraro, Giovanni Misciagna
{"title":"The systemic evolutionary theory of the origin of cancer (SETOC): an update.","authors":"Antonio Mazzocca, Giovanni Ferraro, Giovanni Misciagna","doi":"10.1186/s10020-025-01069-w","DOIUrl":"10.1186/s10020-025-01069-w","url":null,"abstract":"<p><p>The Systemic Evolutionary Theory of the Origin of Cancer (SETOC) is a recently proposed theory founded on two primary principles: the cooperative and endosymbiotic process of cell evolution as described by Lynn Margulis, and the integration of complex systems operating in eukaryotic cells, which is a core concept in systems biology. The SETOC proposes that malignant transformation occurs when cells undergo a continuous adaptation process in response to long-term injuries, leading to tissue remodeling, chronic inflammation, fibrosis, and ultimately cancer. This process involves a maladaptive response, wherein the 'endosymbiotic contract' between the nuclear-cytoplasmic system (derived from the primordial archaeal cell) and the mitochondrial system (derived from the primordial α-proteobacterium) gradually breaks down. This ultimately leads to uncoordinated behaviors and functions in transformed cells. The decoupling of the two cellular subsystems causes transformed cells to acquire phenotypic characteristics analogous to those of unicellular organisms, as well as certain biological features of embryonic development that are normally suppressed. These adaptive changes enable cancer cells to survive in the harsh tumor microenvironment characterized by low oxygen concentrations, inadequate nutrients, increased catabolic waste, and increased acidity. De-endosymbiosis reprograms the sequential metabolic functions of glycolysis, the TCA cycle, and oxidative phosphorylation (OxPhos). This leads to increased lactate fermentation (Warburg effect), respiratory chain dysfunction, and TCA cycle reversal. Here, we present an updated version of the SETOC that incorporates the fundamental principles outlined by this theory and integrates the epistemological approach used to develop it.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"12"},"PeriodicalIF":6.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decreased expression of LEF1 caused defective decidualization by inhibiting IL-11 expression in patients with adenomyosis. 在子宫腺肌症患者中,LEF1表达的降低通过抑制IL-11表达而导致去细胞化缺陷。
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-10 DOI: 10.1186/s10020-024-01054-9
Jingru Duan, Xiaowei Zhou, Hanfei Zhu, Mingjuan Zhou, Mengyu Liu, Yan Zhou, Wenzhu Li, Bufang Xu, Aijun Zhang
{"title":"Decreased expression of LEF1 caused defective decidualization by inhibiting IL-11 expression in patients with adenomyosis.","authors":"Jingru Duan, Xiaowei Zhou, Hanfei Zhu, Mingjuan Zhou, Mengyu Liu, Yan Zhou, Wenzhu Li, Bufang Xu, Aijun Zhang","doi":"10.1186/s10020-024-01054-9","DOIUrl":"10.1186/s10020-024-01054-9","url":null,"abstract":"<p><p>Reduced lymphoid enhancer-binding factor 1 (LEF1) expression in patients with adenomyosis during the mid-secretory phase leads to impaired endometrial receptivity, affecting embryo implantation. This study investigated the molecular mechanisms underlying reduced endometrial receptivity in 25 adenomyosis patients and 25 controls. Functional experiments were conducted using human endometrial stromal cells (HESCs) and TERT-immortalized HESCs(T-HESCs), with final validation performed using a mouse model. Western blot and quantitative real-time polymerase chain reaction (RT-qPCR) analyses revealed that patients with adenomyosis showed a marked decrease in LEF1 expression in the stromal cells of the endometrium during the mid-secretory phase. In vitro experiments demonstrated that LEF1 knockdown in stromal cells led to impaired decidualization. Transcriptome sequencing, dual-luciferase reporter assays, and chromatin immunoprecipitation (ChIP) experiments showed that LEF1 could bind to the promoter region of interleukin (IL)-11 and promote its transcription, and IL-11 expression was also found to be downregulated in adenomyosis patients. Overexpression of IL-11 rescued the impaired decidualization caused by decreased LEF1 expression. In the in vitro co-culture model, LEF1/IL-11 knockdown led to a reduction in embryo implantation area, which was partially restored upon IL-11 overexpression. In the adenomyosis mouse model, we observed a decrease in LEF1 expression and a reduction in implantation sites compared to control mice, accompanied by impaired decidualization and receptivity. Notably, supplementation with IL-11 restored the number of implantation sites. The decrease in fertility due to reduced endometrial receptivity in adenomyosis patients is a significant clinical issue in assisted reproductive technology. This research provides insights into one potential molecular mechanism underlying this decreased receptivity, with a specific focus on the reduced expression of LEF1 in the endometrial stromal cells during the mid-secretory phase in adenomyosis patients. Our findings offer new perspectives for clinical strategies to improve endometrial receptivity in patients with adenomyosis, potentially enhancing their chances of successful pregnancy.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"10"},"PeriodicalIF":6.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AM1241 inhibits chondrocyte inflammation and ECM degradation through the Nrf2/HO-1 and NF-κB pathways and alleviates osteoarthritis in mice.
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-10 DOI: 10.1186/s10020-024-01012-5
Zhuan Zou, Songmu Pan, Changzheng Sun, Jiyong Wei, Yi Xu, Kaizhen Xiao, Jinmin Zhao, Ronghe Gu
{"title":"AM1241 inhibits chondrocyte inflammation and ECM degradation through the Nrf2/HO-1 and NF-κB pathways and alleviates osteoarthritis in mice.","authors":"Zhuan Zou, Songmu Pan, Changzheng Sun, Jiyong Wei, Yi Xu, Kaizhen Xiao, Jinmin Zhao, Ronghe Gu","doi":"10.1186/s10020-024-01012-5","DOIUrl":"https://doi.org/10.1186/s10020-024-01012-5","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the impact of AM1241 on lipopolysaccharide (LPS)-induced chondrocyte inflammation in mice and its potential mechanism for improving osteoarthritis (OA).</p><p><strong>Methods: </strong>The OA mice model was established employing the refined Hulth method. The impact of different concentrations of AM1241 on mice chondrocyte activity was detected using CCK-8. Changes in the levels of LPS-induced inflammatory factors and cartilage extracellular matrix (ECM) degradation in chondrocytes were determined by western blot, RT-qPCR, ELISA, and immunofluorescence assays, respectively. The specific action modes and binding sites of AM1241 with NEMO/IκB kinases (IKKs) in the NF-κB pathway and Keap1 protein in the Nrf2 pathway were predicted via molecular docking and molecular dynamics simulation, and the NF-κB and Nrf2 pathways were detected using western blot and immunofluorescence. In vivo, the impact of AM1241 on OA mice was analyzed through safranin-fast green staining, IHC staining, Mankin score, and microCT.</p><p><strong>Results: </strong>AM1241 inhibited the levels of LPS-induced transforming growth factor-β (TGF-β1), tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), matrix metalloproteinase-13 (MMP-13), and a disintegrin and metalloproteinase with thrombospondin motif 5 (ADAMTS-5) and diminished the degradation of type II collagen and Aggrecan. For the mechanism, AM1241 regulated the NF-kB and Nrf2/HO-1 signaling pathways by binding to NEMO/IKKβ and Keap1 target proteins and suppressed the activation of the NF-κB signaling pathway by activating the Nrf2 in chondrocytes. In vivo, AM1241 inhibited bone anabolism, mitigated articular cartilage hyperplasia and wear, and reduced the Mankin score in mice, thereby hindering the development of OA.</p><p><strong>Conclusion: </strong>AM1241 inhibited activation of the NF-κB signaling pathway via activating Nrf2. It suppressed the expression of inflammation factors and the degradation of ECM in vitro, and improved OA in mice in vivo, suggesting its potential as an effective drug candidate for the treatment of OA. The remarkable efficacy of AM1241 in alleviating murine OA positions it as a potential therapeutic strategy in the clinical management of OA diseases.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"9"},"PeriodicalIF":6.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143055931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An eCIRP inhibitor attenuates fibrosis and ferroptosis in ischemia and reperfusion induced chronic kidney disease. 一种eCIRP抑制剂减轻缺血再灌注引起的慢性肾脏疾病的纤维化和铁下垂。
IF 6 2区 医学
Molecular Medicine Pub Date : 2025-01-10 DOI: 10.1186/s10020-025-01071-2
Fangming Zhang, Zhijian Hu, Asha Jacob, Max Brenner, Ping Wang
{"title":"An eCIRP inhibitor attenuates fibrosis and ferroptosis in ischemia and reperfusion induced chronic kidney disease.","authors":"Fangming Zhang, Zhijian Hu, Asha Jacob, Max Brenner, Ping Wang","doi":"10.1186/s10020-025-01071-2","DOIUrl":"10.1186/s10020-025-01071-2","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) is a leading cause of death in the United States, and renal fibrosis represents a pathologic hallmark of CKD. Extracellular cold-inducible RNA-binding protein (eCIRP) is a stress response protein involved in acute inflammation, tissue injury and regulated cell death. However, the role of eCIRP in chronic inflammation and tissue injury has not been elucidated. We hypothesize that eCIRP is involved in renal ischemia/reperfusion (RIR)-induced CKD and that C23, an antagonist to eCIRP, is beneficial in attenuating renal fibrosis and ferroptosis in RIR-induced CKD.</p><p><strong>Methods: </strong>C57BL/6 (WT) or CIRP<sup>-/-</sup> mice underwent renal injury with total blockage of blood perfusion by clamping bilateral renal pedicles for 28 min. In the WT mice at the time of reperfusion, they were treated with C23 (8 mg/kg) or vehicle. Blood and kidneys were harvested for further analysis at 21 days thereafter. In a separate cohort, mice underwent bilateral RIR and treatment with C23 or vehicle and were then subjected to left nephrectomy 72 h thereafter. Mice were then monitored for additional 19 days, and glomerular filtration rate (GFR) was assessed using a noninvasive transcutaneous method.</p><p><strong>Results: </strong>In the RIR-induced CKD, CIRP<sup>-/-</sup> mice showed decreased collagen deposition, fibronectin staining, and renal injury as compared to the WT mice. Administration of C23 ameliorated renal fibrosis by decreasing the expression of active TGF-β1, α-SMA, collagen deposition, fibronectin and macrophage infiltration to the kidneys. Furthermore, intervention with C23 significantly decreased renal ferroptosis by reducing iron accumulation, increasing the expression of glutathione peroxidase 4 (GPX4) and lipid peroxidation in the kidneys of RIR-induced CKD mice. Treatment with C23 also attenuated BUN and creatinine. Finally, GFR was significantly decreased in RIR mice with left nephrectomy and C23 treatment partially prevented their decrease.</p><p><strong>Conclusion: </strong>Our data show that eCIRP plays an important role in RIR-induced CKD. Treatment with C23 decreased renal inflammation, alleviated chronic renal injury and fibrosis, and inhibited ferroptosis in the RIR-induced CKD mice.</p>","PeriodicalId":18813,"journal":{"name":"Molecular Medicine","volume":"31 1","pages":"11"},"PeriodicalIF":6.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信